-
1
-
-
0022499547
-
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin
-
Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986; 324: 73-76.
-
(1986)
Nature
, vol.324
, pp. 73-76
-
-
Hirano, T.1
Yasukawa, K.2
Harada, H.3
-
2
-
-
0024360388
-
The biology of interleukin-6
-
Kishimoto T. The biology of interleukin-6. Blood. 1989; 74: 1-10.
-
(1989)
Blood
, vol.74
, pp. 1-10
-
-
Kishimoto, T.1
-
3
-
-
17644368573
-
Interleukin-6: From basic science to medicine-40 years in immunology
-
Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005; 23: 1-21.
-
(2005)
Annu Rev Immunol
, vol.23
, pp. 1-21
-
-
Kishimoto, T.1
-
4
-
-
15444356801
-
Interleukin-6
-
Snapper CM, ed., New Jersey: John Wiley & Sons Ltd
-
Tanaka T, Katada Y, Suemura M, et al. Interleukin-6. In: Snapper CM, ed. Cytokine regulation of humoral immunity: basic and clinical aspects. New Jersey: John Wiley & Sons Ltd.; 1996; 251-272.
-
(1996)
Cytokine Regulation of Humoral Immunity: Basic and Clinical Aspects
, pp. 251-272
-
-
Tanaka, T.1
Katada, Y.2
Suemura, M.3
-
6
-
-
0037066427
-
The danger model: A renewed sense of self
-
Matzinger P. The danger model: a renewed sense of self. Science. 2002; 296: 301-305.
-
(2002)
Science
, vol.296
, pp. 301-305
-
-
Matzinger, P.1
-
7
-
-
0025190892
-
Interleukin-6 and the acute phase response
-
Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990; 265: 621-636.
-
(1990)
Biochem J
, vol.265
, pp. 621-636
-
-
Heinrich, P.C.1
Castell, J.V.2
Andus, T.3
-
8
-
-
0034234716
-
Hepatic cytochrome p450 down-regulation during aseptic inflammation in the mouse is interleu-kin 6 dependent
-
Siewert E, Bort R, Kluge R, et al. Hepatic cytochrome p450 down-regulation during aseptic inflammation in the mouse is interleu-kin 6 dependent. Hepatology. 2000; 32: 49-55.
-
(2000)
Hepatology
, vol.32
, pp. 49-55
-
-
Siewert, E.1
Bort, R.2
Kluge, R.3
-
9
-
-
49149095841
-
Transcriptional complex formation of c-Fos, STAT3, and Hepatocyte NF-1alpha is essential for cyto-kine-driven C-reactive protein gene expression
-
Nishikawa T, Hagihara K, Serada S, et al. Transcriptional complex formation of c-Fos, STAT3, and Hepatocyte NF-1alpha is essential for cyto-kine-driven C-reactive protein gene expression. J Immunol. 2008; 180: 3492-3501.
-
(2008)
J Immunol
, vol.180
, pp. 3492-3501
-
-
Nishikawa, T.1
Hagihara, K.2
Serada, S.3
-
10
-
-
58149154996
-
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocili-zumab, in patients with rheumatoid arthritis and Castleman disease
-
Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocili-zumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112: 3959-3964.
-
(2008)
Blood
, vol.112
, pp. 3959-3964
-
-
Nishimoto, N.1
Terao, K.2
Mima, T.3
-
11
-
-
2342510407
-
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
-
Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271-1276.
-
(2004)
J Clin Invest
, vol.113
, pp. 1271-1276
-
-
Nemeth, E.1
Rivera, S.2
Gabayan, V.3
-
14
-
-
77954096689
-
IL-6: Regulator of Treg/Th17 balance
-
Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010; 40: 1830-1835.
-
(2010)
Eur J Immunol
, vol.40
, pp. 1830-1835
-
-
Kimura, A.1
Kishimoto, T.2
-
15
-
-
80053262406
-
Human FoxP3+ regulatory T cells in systemic autoimmune diseases
-
Miyara M, Gorochov G, Ehrenstein M, et al. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev. 2011; 10: 744-755.
-
(2011)
Autoimmun Rev
, vol.10
, pp. 744-755
-
-
Miyara, M.1
Gorochov, G.2
Ehrenstein, M.3
-
16
-
-
0023803252
-
IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells
-
Okada M, Kitahara M, Kishimoto S, et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol. 1988; 141: 1543-1549.
-
(1988)
J Immunol
, vol.141
, pp. 1543-1549
-
-
Okada, M.1
Kitahara, M.2
Kishimoto, S.3
-
17
-
-
0024446495
-
Interleukin-6 is a potent thrombopoietic factor in vivo in mice
-
Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989; 74: 1241-1244.
-
(1989)
Blood
, vol.74
, pp. 1241-1244
-
-
Ishibashi, T.1
Kimura, H.2
Shikama, Y.3
-
18
-
-
13344250490
-
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
-
Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996; 11: 88-95.
-
(1996)
J Bone Miner Res
, vol.11
, pp. 88-95
-
-
Kotake, S.1
Sato, K.2
Kim, K.J.3
-
19
-
-
0038798085
-
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis
-
Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003; 48: 1521-1529.
-
(2003)
Arthritis Rheum
, vol.48
, pp. 1521-1529
-
-
Nakahara, H.1
Song, J.2
Sugimoto, M.3
-
20
-
-
0343019918
-
Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes
-
Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA. 1989; 86: 6367-6371.
-
(1989)
Proc Natl Acad Sci USA
, vol.86
, pp. 6367-6371
-
-
Grossman, R.M.1
Krueger, J.2
Yourish, D.3
-
21
-
-
0025989368
-
Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6
-
Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol. 1991; 97: 686-692.
-
(1991)
J Invest Dermatol
, vol.97
, pp. 686-692
-
-
Duncan, M.R.1
Berman, B.2
-
22
-
-
0023849455
-
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
-
Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988; 332: 83-85.
-
(1988)
Nature
, vol.332
, pp. 83-85
-
-
Kawano, M.1
Hirano, T.2
Matsuda, T.3
-
23
-
-
0345317621
-
IgG1 plasmacytosis in interleu-kin 6 transgenic mice
-
Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleu-kin 6 transgenic mice. Proc Natl Acad Sci USA. 1989; 86: 7547-7551.
-
(1989)
Proc Natl Acad Sci USA
, vol.86
, pp. 7547-7551
-
-
Suematsu, S.1
Matsuda, T.2
Aozasa, K.3
-
24
-
-
0024805715
-
Involvement of IL-6 in mesangial proliferative glomerulonephritis
-
Horii Y, Muraguchi A, Iwano M, et al. Involvement of IL-6 in mesangial proliferative glomerulonephritis. J Immunol. 1989; 143: 3949-3955.
-
(1989)
J Immunol
, vol.143
, pp. 3949-3955
-
-
Horii, Y.1
Muraguchi, A.2
Iwano, M.3
-
25
-
-
0023685762
-
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor
-
Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science. 1988; 241: 825-828.
-
(1988)
Science
, vol.241
, pp. 825-828
-
-
Yamasaki, K.1
Taga, T.2
Hirata, Y.3
-
26
-
-
0026485304
-
Interleukin-6 and its receptor: A paradigm for cytokines
-
Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science. 1992; 258: 593-597.
-
(1992)
Science
, vol.258
, pp. 593-597
-
-
Kishimoto, T.1
Akira, S.2
Taga, T.3
-
27
-
-
0025630163
-
Molecular cloning and expression of an IL-6 signal transducer, gp130
-
Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990; 63: 1149-1157.
-
(1990)
Cell
, vol.63
, pp. 1149-1157
-
-
Hibi, M.1
Murakami, M.2
Saito, M.3
-
28
-
-
0029084805
-
Interleukin-6 family of cytokines and gp130
-
Kishimoto T, Akira S, Narazaki M, et al. Interleukin-6 family of cytokines and gp130. Blood. 1995; 86: 1243-1254.
-
(1995)
Blood
, vol.86
, pp. 1243-1254
-
-
Kishimoto, T.1
Akira, S.2
Narazaki, M.3
-
29
-
-
0030890718
-
Gp130 and the interleukin-6 family of cytokines
-
Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997; 15: 797-819.
-
(1997)
Annu Rev Immunol
, vol.15
, pp. 797-819
-
-
Taga, T.1
Kishimoto, T.2
-
30
-
-
0027199126
-
IL-6-induced homodimeriza-tion of gp130 and associated activation of a tyrosine kinase
-
Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodimeriza-tion of gp130 and associated activation of a tyrosine kinase. Science. 1993; 260: 1808-1810.
-
(1993)
Science
, vol.260
, pp. 1808-1810
-
-
Murakami, M.1
Hibi, M.2
Nakagawa, N.3
-
31
-
-
0038609651
-
Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex
-
Boulanger MJ, Chow DC, Brevnova EE, et al. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science. 2003; 300: 2101-2104.
-
(2003)
Science
, vol.300
, pp. 2101-2104
-
-
Boulanger, M.J.1
Chow, D.C.2
Brevnova, E.E.3
-
32
-
-
80052358980
-
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
-
Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011; 121: 3375-3383.
-
(2011)
J Clin Invest
, vol.121
, pp. 3375-3383
-
-
Jones, S.A.1
Scheller, J.2
Rose-John, S.3
-
33
-
-
0027421831
-
Interleukin-6 in biology and medicine
-
Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol. 1993; 54: 1-78.
-
(1993)
Adv Immunol
, vol.54
, pp. 1-78
-
-
Akira, S.1
Taga, T.2
Kishimoto, T.3
-
34
-
-
0035892118
-
Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpes virus
-
Aoki Y, Narazaki M, Kishimoto T, et al. Receptor engagement by viral interleukin-6 encoded by Kaposi sarcoma-associated herpes virus. Blood. 2001; 98: 3042-3049.
-
(2001)
Blood
, vol.98
, pp. 3042-3049
-
-
Aoki, Y.1
Narazaki, M.2
Kishimoto, T.3
-
35
-
-
0025183151
-
Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice
-
Brandt SJ, Bodine DM, Dunbar CE, et al. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest. 1990; 86: 592-599.
-
(1990)
J Clin Invest
, vol.86
, pp. 592-599
-
-
Brandt, S.J.1
Bodine, D.M.2
Dunbar, C.E.3
-
36
-
-
84869830784
-
Immunotherapy of tocilizumab for rheumatoid arthritis
-
S6-S01
-
Tanaka T, Kishimoto T. Immunotherapy of tocilizumab for rheumatoid arthritis. J Clin Cell Immunol. 2011;: S6-S01.
-
(2011)
J Clin Cell Immunol
-
-
Tanaka, T.1
Kishimoto, T.2
-
37
-
-
0032536542
-
Interleukin 6 is required for the development of collagen-induced arthritis
-
Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998; 187: 461-468.
-
(1998)
J Exp Med
, vol.187
, pp. 461-468
-
-
Alonzi, T.1
Fattori, E.2
Lazzaro, D.3
-
38
-
-
0032429668
-
Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis
-
Takagi N, Mihara M, Moriya Y, et al. Blockade of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 1998; 41: 2117-2121.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 2117-2121
-
-
Takagi, N.1
Mihara, M.2
Moriya, Y.3
-
39
-
-
13144259627
-
Interleukin 6 plays a key role in the development of antigen-induced arthritis
-
Ohshima S, Saeki Y, Mima T, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA. 1998; 95: 8222-8226.
-
(1998)
Proc Natl Acad Sci USA
, vol.95
, pp. 8222-8226
-
-
Ohshima, S.1
Saeki, Y.2
Mima, T.3
-
40
-
-
0033503152
-
Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice
-
Sasai M, Saeki Y, Ohshima S, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum. 1999; 42: 1635-1643.
-
(1999)
Arthritis Rheum
, vol.42
, pp. 1635-1643
-
-
Sasai, M.1
Saeki, Y.2
Ohshima, S.3
-
41
-
-
0035990220
-
Antigen induced arthritis (AIA) can be transferred by bone marrow transplantation: Evidence that interleukin 6 is essential for induction of AIA
-
Kobayashi H, Ohshima S, Nishioka K, et al. Antigen induced arthritis (AIA) can be transferred by bone marrow transplantation: evidence that interleukin 6 is essential for induction of AIA. J Rheumatol. 2002; 29: 1176-1182.
-
(2002)
J Rheumatol
, vol.29
, pp. 1176-1182
-
-
Kobayashi, H.1
Ohshima, S.2
Nishioka, K.3
-
42
-
-
31044449633
-
Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis
-
Wong PK, Quinn JM, Sims NA, et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum. 2006; 54: 158-168.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 158-168
-
-
Wong, P.K.1
Quinn, J.M.2
Sims, N.A.3
-
43
-
-
4344590199
-
Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice
-
Hata H, Sakaguchi N, Yoshitomi H, et al. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest. 2004; 114: 582-588.
-
(2004)
J Clin Invest
, vol.114
, pp. 582-588
-
-
Hata, H.1
Sakaguchi, N.2
Yoshitomi, H.3
-
44
-
-
33846456970
-
T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis
-
Hirota K, Hashimoto M, Yoshitomi H, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med. 2007; 204: 41-47.
-
(2007)
J Exp Med
, vol.204
, pp. 41-47
-
-
Hirota, K.1
Hashimoto, M.2
Yoshitomi, H.3
-
45
-
-
0029148912
-
Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans
-
Iwakura Y, Saijo S, Kioka Y, et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J Immunol. 1995; 155: 1588-1598.
-
(1995)
J Immunol
, vol.155
, pp. 1588-1598
-
-
Iwakura, Y.1
Saijo, S.2
Kioka, Y.3
-
46
-
-
0037037586
-
A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis
-
Atsumi T, Ishihara K, Kamimura D, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med. 2002; 196: 979-990.
-
(2002)
J Exp Med
, vol.196
, pp. 979-990
-
-
Atsumi, T.1
Ishihara, K.2
Kamimura, D.3
-
47
-
-
57349083145
-
Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses
-
Fujimoto M, Serada S, Mihara M, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum. 2008; 58: 3710-3719.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 3710-3719
-
-
Fujimoto, M.1
Serada, S.2
Mihara, M.3
-
48
-
-
40549102753
-
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase
-
Iwanami K, Matsumoto I, Tanaka-Watanabe Y, et al. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum. 2008; 58: 754-763.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 754-763
-
-
Iwanami, K.1
Matsumoto, I.2
Tanaka-Watanabe, Y.3
-
49
-
-
0031861643
-
IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice
-
Mihara M, Takagi N, Takeda Y, et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol. 1998; 112: 397-402.
-
(1998)
Clin Exp Immunol
, vol.112
, pp. 397-402
-
-
Mihara, M.1
Takagi, N.2
Takeda, Y.3
-
50
-
-
33750011260
-
Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus
-
Liang B, Gardner DB, Griswold DE, et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology. 2006; 119: 296-305.
-
(2006)
Immunology
, vol.119
, pp. 296-305
-
-
Liang, B.1
Gardner, D.B.2
Griswold, D.E.3
-
51
-
-
73949099325
-
Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling
-
Pflegerl P, Vesely P, Hantusch B, et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci USA. 2009; 106: 20423-20428.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 20423-20428
-
-
Pflegerl, P.1
Vesely, P.2
Hantusch, B.3
-
52
-
-
83455230778
-
Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma
-
Kitaba S, Murota H, Terao M, et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol. 2012; 80: 165-176.
-
(2012)
Am J Pathol
, vol.80
, pp. 165-176
-
-
Kitaba, S.1
Murota, H.2
Terao, M.3
-
53
-
-
80155206307
-
Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling
-
Yoshizaki A, Yanaba K, Ogawa A, et al. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 2011; 63: 3575-3585.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 3575-3585
-
-
Yoshizaki, A.1
Yanaba, K.2
Ogawa, A.3
-
54
-
-
68049088818
-
Therapeutic effects of inter-leukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A
-
Okiyama N, Sugihara T, Iwakura Y, et al. Therapeutic effects of inter-leukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum. 2009; 60: 2505-2512.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 2505-2512
-
-
Okiyama, N.1
Sugihara, T.2
Iwakura, Y.3
-
55
-
-
77954952358
-
Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses
-
Hohki S, Ohguro N, Haruta H, et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res. 2010; 91: 162-170.
-
(2010)
Exp Eye Res
, vol.91
, pp. 162-170
-
-
Hohki, S.1
Ohguro, N.2
Haruta, H.3
-
56
-
-
79961008060
-
Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis
-
Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2011; 52: 3264-3271.
-
(2011)
Invest Ophthalmol Vis Sci
, vol.52
, pp. 3264-3271
-
-
Haruta, H.1
Ohguro, N.2
Fujimoto, M.3
-
57
-
-
48249148236
-
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis
-
Serada S, Fujimoto M, Mihara M, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2008; 105: 9041-9046.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 9041-9046
-
-
Serada, S.1
Fujimoto, M.2
Mihara, M.3
-
58
-
-
81755184476
-
Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases
-
Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS lett. 2011; 585: 3699-3709.
-
(2011)
FEBS Lett
, vol.585
, pp. 3699-3709
-
-
Tanaka, T.1
Narazaki, M.2
Kishimoto, T.3
-
60
-
-
2642558925
-
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: A multi-center, double-blind, placebo-controlled trial
-
Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multi-center, double-blind, placebo-controlled trial. Arthritis Rheum. 2004; 50: 1761-1769.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 1761-1769
-
-
Nishimoto, N.1
Yoshizaki, K.2
Miyasaka, N.3
-
61
-
-
33749363027
-
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
-
CHARISMA Study Group
-
Maini RN, Taylor PC, Szechinski J, et al; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006; 54: 2817-2829.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2817-2829
-
-
Maini, R.N.1
Taylor, P.C.2
Szechinski, J.3
-
62
-
-
70349402169
-
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study
-
Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009; 68: 1580-1584.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1580-1584
-
-
Nishimoto, N.1
Miyasaka, N.2
Yamamoto, K.3
-
63
-
-
73449118587
-
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study
-
Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010; 69: 88-96.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 88-96
-
-
Jones, G.1
Sebba, A.2
Gu, J.3
-
64
-
-
40749114497
-
OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomized trial
-
Smolen JS, Beaulieu A, Rubbert-Roth A, et al; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008; 371: 987-997.
-
(2008)
Lancet
, vol.371
, pp. 987-997
-
-
Smolen, J.S.1
Beaulieu, A.2
Rubbert-Roth, A.3
-
65
-
-
54949150604
-
Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The TCZ in combination with traditional disease-modifying antirheumatic drug therapy study
-
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with TCZ reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the TCZ in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008; 58: 2968-2980.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 2968-2980
-
-
Genovese, M.C.1
McKay, J.D.2
Nasonov, E.L.3
-
66
-
-
52149099504
-
IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: Results from a 24-week multicentre randomized placebo controlled trial
-
Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with TCZ improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomized placebo controlled trial. Ann Rheum Dis. 2008; 67: 1516-1523.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 1516-1523
-
-
Emery, P.1
Keystone, E.2
Tony, H.P.3
-
67
-
-
31544451391
-
Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement
-
Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005; 7: R1281-288.
-
(2005)
Arthritis Res Ther
, vol.7
-
-
Woo, P.1
Wilkinson, N.2
Prieur, A.M.3
-
68
-
-
20144362101
-
Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis
-
Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818-825.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 818-825
-
-
Yokota, S.1
Miyamae, T.2
Imagawa, T.3
-
69
-
-
40749152243
-
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomized, double-blind, placebo-controlled, withdrawal phase III trial
-
Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 1006-1998.
-
(2008)
Lancet
, vol.371
, pp. 1006-1998
-
-
Yokota, S.1
Imagawa, T.2
Mori, M.3
-
70
-
-
84869843659
-
Tocilizumab in patients with systemic juvenile idiopathic arthritis: Efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial
-
De Benedetti F, Brunner H, Ruperto N, et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial. Arthritis Rheum. 2010; 62(Suppl 10): 1434.
-
(2010)
Arthritis Rheum
, vol.62
, Issue.SUPPL. 10
, pp. 1434
-
-
de Benedetti, F.1
Brunner, H.2
Ruperto, N.3
-
71
-
-
84871090569
-
Efficacy and safety of tocil-izumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): Tender 52-week data
-
De Benedetti F, Brunner H, Ruperto N, et al. Efficacy and safety of tocil-izumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data. Pediat Rheumatol. 2011; 9(Suppl 1): 164.
-
(2011)
Pediat Rheumatol
, vol.9
, Issue.SUPPL. 1
, pp. 164
-
-
de Benedetti, F.1
Brunner, H.2
Ruperto, N.3
-
72
-
-
0033959608
-
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
-
Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000; 95: 56-61.
-
(2000)
Blood
, vol.95
, pp. 56-61
-
-
Nishimoto, N.1
Sasai, M.2
Shima, Y.3
-
73
-
-
27144488346
-
Humanized an-ti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
-
Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized an-ti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005; 106: 2627-2632.
-
(2005)
Blood
, vol.106
, pp. 2627-2632
-
-
Nishimoto, N.1
Kanakura, Y.2
Aozasa, K.3
-
74
-
-
75749113331
-
Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
-
Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010; 62: 542-552.
-
(2010)
Arthritis Rheum
, vol.62
, pp. 542-552
-
-
Illei, G.G.1
Shirota, Y.2
Yarboro, C.H.3
-
76
-
-
84859757911
-
Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urti-carial vasculitis
-
Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urti-carial vasculitis. J Clin Rheumatol. 2012; 18: 92-95.
-
(2012)
J Clin Rheumatol
, vol.18
, pp. 92-95
-
-
Makol, A.1
Gibson, L.E.2
Michet, C.J.3
-
77
-
-
78049421175
-
The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
-
Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford). 2010; 49: 2408-2412.
-
(2010)
Rheumatology (Oxford)
, vol.49
, pp. 2408-2412
-
-
Shima, Y.1
Kuwahara, Y.2
Murota, H.3
-
78
-
-
79959478448
-
Therapeutic effect of tocili-zumab on two patients with polymyositis
-
Narazaki M, Hagihara K, Shima Y, et al. Therapeutic effect of tocili-zumab on two patients with polymyositis. Rheumatology (Oxford). 2011; 50: 1344-1346.
-
(2011)
Rheumatology (Oxford)
, vol.50
, pp. 1344-1346
-
-
Narazaki, M.1
Hagihara, K.2
Shima, Y.3
-
79
-
-
79955751346
-
Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series
-
Seitz M, Reichenbach S, Bonel HM, et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly. 2011; 141: w13156.
-
(2011)
Swiss Med Wkly
, vol.141
-
-
Seitz, M.1
Reichenbach, S.2
Bonel, H.M.3
-
80
-
-
80052495918
-
Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis
-
Beyer C, Axmann R, Sahinbegovic E, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis. 2011; 70: 1874-1875.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1874-1875
-
-
Beyer, C.1
Axmann, R.2
Sahinbegovic, E.3
-
81
-
-
80052318064
-
Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis
-
Sciascia S, Rossi D, Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol. 2011; 38: 2080-2081.
-
(2011)
J Rheumatol
, vol.38
, pp. 2080-2081
-
-
Sciascia, S.1
Rossi, D.2
Roccatello, D.3
-
82
-
-
84855162831
-
Tocilizumab: A novel therapy for patients with large-vessel vasculitis
-
Salvarani C, Magnani L, Catanoso M, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (0xford). 2012; 51: 151-156.
-
(2012)
Rheumatology (0xford)
, vol.51
, pp. 151-156
-
-
Salvarani, C.1
Magnani, L.2
Catanoso, M.3
-
83
-
-
84860566126
-
Efficacy of tocilizumab in refractory giant cell arteritis
-
Vinit J, Bielefeld P, Muller G, et al. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine. 2012; 79: 317-318.
-
(2012)
Joint Bone Spine
, vol.79
, pp. 317-318
-
-
Vinit, J.1
Bielefeld, P.2
Muller, G.3
-
85
-
-
42449088420
-
Successful treatment of a patient with Takayasu arteritis using a humanized an-ti-interleukin-6 receptor antibody
-
Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. Successful treatment of a patient with Takayasu arteritis using a humanized an-ti-interleukin-6 receptor antibody. Arthritis Rheum. 2008; 58: 1197-200.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 1197-1200
-
-
Nishimoto, N.1
Nakahara, H.2
Yoshio-Hoshino, N.3
-
86
-
-
84863756702
-
Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers
-
[Epub ahead of print]
-
Salvarani C, Magnani L, Catanoso MG, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol. 2012; [Epub ahead of print].
-
(2012)
Clin Exp Rheumatol
-
-
Salvarani, C.1
Magnani, L.2
Catanoso, M.G.3
-
87
-
-
84863744973
-
One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab
-
[Epub ahead of print]
-
Bredemeier M, Rocha CM, Barbosa MV, et al. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol. 2012; [Epub ahead of print].
-
(2012)
Clin Exp Rheumatol
-
-
Bredemeier, M.1
Rocha, C.M.2
Barbosa, M.V.3
-
88
-
-
84857915035
-
Efficacy of tocil-izumab in rituximab-refractory cryoglobulinemia vasculitis
-
Cohen C, Mekinian A, Saidenberg-Kermanach N, et al. Efficacy of tocil-izumab in rituximab-refractory cryoglobulinemia vasculitis. Ann Rheum Dis. 2012; 71: 628-629.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 628-629
-
-
Cohen, C.1
Mekinian, A.2
Saidenberg-Kermanach, N.3
-
89
-
-
80053159298
-
Complete remission of myelop-eroxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody
-
Sumida K, Ubara Y, Suwabe T, et al. Complete remission of myelop-eroxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (0xford). 2011; 50: 1928-1930.
-
(2011)
Rheumatology (0xford)
, vol.50
, pp. 1928-1930
-
-
Sumida, K.1
Ubara, Y.2
Suwabe, T.3
-
90
-
-
79960393209
-
Successful treatment with humanized anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis
-
Sumida K, Ubara Y, Takemoto F, et al. Successful treatment with humanized anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin Exp Rheumatol. 2011; 29(1 Suppl 64): S133.
-
(2011)
Clin Exp Rheumatol
, vol.29
, Issue.1 SUPPL. 64
-
-
Sumida, K.1
Ubara, Y.2
Takemoto, F.3
-
91
-
-
11144358366
-
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
-
Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004; 126: 989-996.
-
(2004)
Gastroenterology
, vol.126
, pp. 989-996
-
-
Ito, H.1
Takazoe, M.2
Fukuda, Y.3
-
92
-
-
61349092994
-
Sustained response to tocili-zumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis
-
Kawai M, Hagihara K, Hirano T, et al. Sustained response to tocili-zumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford). 2009; 48: 318-319.
-
(2009)
Rheumatology (Oxford)
, vol.48
, pp. 318-319
-
-
Kawai, M.1
Hagihara, K.2
Hirano, T.3
-
93
-
-
84860257586
-
Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-α failure in a patient with relapsing poly-chondritis complicated by aortitis
-
Narshi CB, Allard SA. Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-α failure in a patient with relapsing poly-chondritis complicated by aortitis. Rheumatology (Oxford). 2012; 51: 952-953.
-
(2012)
Rheumatology (Oxford)
, vol.51
, pp. 952-953
-
-
Narshi, C.B.1
Allard, S.A.2
-
94
-
-
83255170953
-
Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocili-zumab
-
Nishida S, Kawasaki T, Kashiwagi H, et al. Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocili-zumab. Mod Rheumatol. 2011; 21: 420-422.
-
(2011)
Mod Rheumatol
, vol.21
, pp. 420-422
-
-
Nishida, S.1
Kawasaki, T.2
Kashiwagi, H.3
-
95
-
-
79960206055
-
Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy
-
Yuzuriha A, Saitoh T, Koiso H, et al. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol. 2011; 126: 147-150.
-
(2011)
Acta Haematol
, vol.126
, pp. 147-150
-
-
Yuzuriha, A.1
Saitoh, T.2
Koiso, H.3
-
96
-
-
84867115230
-
Tocil-izumab for treating refractory haemolytic anemia in a patient with systemic lupus erythematosus
-
[Epub ahead of print]
-
GarciaHernandez FJ, GonzalezLeon R, CastilloPalma MJ, et al. Tocil-izumab for treating refractory haemolytic anemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 2012; [Epub ahead of print].
-
(2012)
Rheumatology (Oxford)
-
-
Garciahernandez, F.J.1
Gonzalezleon, R.2
Castillopalma, M.J.3
-
97
-
-
0036898472
-
Humanized monoclonal an-ti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease
-
Iwamoto M, Nara H, Hirata D, et al. Humanized monoclonal an-ti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 2002; 46: 3388-3389.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 3388-3389
-
-
Iwamoto, M.1
Nara, H.2
Hirata, D.3
-
98
-
-
60149096148
-
A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years
-
Nakahara H, Mima T, Yoshino-Hoshino N, et al. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol. 2009; 19: 69-72.
-
(2009)
Mod Rheumatol
, vol.19
, pp. 69-72
-
-
Nakahara, H.1
Mima, T.2
Yoshino-Hoshino, N.3
-
99
-
-
58349119558
-
Tocilizumab for multirefractory adult-onset Still's disease
-
De Bandt M. Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis. 2009; 68: 153-154.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 153-154
-
-
de Bandt, M.1
Saint-Marcoux, B.2
-
100
-
-
61549119438
-
Glucocorticoid and cy-closporine refractory adult onset Still's disease successfully treated with tocilizumab
-
Matsumoto K, Nagashima T, Takatori S, et al. Glucocorticoid and cy-closporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol. 2009; 28: 485-487.
-
(2009)
Clin Rheumatol
, vol.28
, pp. 485-487
-
-
Matsumoto, K.1
Nagashima, T.2
Takatori, S.3
-
101
-
-
79952461285
-
The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease
-
Cunha ML, Wagner J, Osawa A, et al. The effect of tocilizumab on the uptake of 18FDG-PET imaging in patients with adult-onset Still's disease. Rheumatology (Oxford). 2010; 49: 1014-1016.
-
(2010)
Rheumatology (Oxford)
, vol.49
, pp. 1014-1016
-
-
Cunha, M.L.1
Wagner, J.2
Osawa, A.3
-
102
-
-
79952108981
-
Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab
-
Sumida K, Ubara Y, Hoshino J, et al. Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol. 2010; 29: 1191-1194.
-
(2010)
Clin Rheumatol
, vol.29
, pp. 1191-1194
-
-
Sumida, K.1
Ubara, Y.2
Hoshino, J.3
-
103
-
-
77949512903
-
Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD)
-
Yoshimura M, Makiyama J, Koga T, et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD). Clin Exp Rheumatol. 2010; 28: 141-142.
-
(2010)
Clin Exp Rheumatol
, vol.28
, pp. 141-142
-
-
Yoshimura, M.1
Makiyama, J.2
Koga, T.3
-
104
-
-
78649326282
-
A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature
-
Perdan-Pirkmajer K, Praprotnik S, Tomsic M. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol. 2010; 29: 1465-1467.
-
(2010)
Clin Rheumatol
, vol.29
, pp. 1465-1467
-
-
Perdan-Pirkmajer, K.1
Praprotnik, S.2
Tomsic, M.3
-
105
-
-
84874848032
-
Case report: Successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease
-
[Epub ahead of print]
-
Naniwa T, Ito R, Watanabe M, et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease. Clin Rheumatol. 2010; [Epub ahead of print].
-
(2010)
Clin Rheumatol
-
-
Naniwa, T.1
Ito, R.2
Watanabe, M.3
-
106
-
-
79959933001
-
Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis
-
Kishida D, Okuda Y, Ohnishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011; 21: 215-218.
-
(2011)
Mod Rheumatol
, vol.21
, pp. 215-218
-
-
Kishida, D.1
Okuda, Y.2
Ohnishi, M.3
-
107
-
-
83555172604
-
Treatment of refractory adult-onset Still's disease with tocilizumab: Report of two cases and review of the literature
-
Thonhofer R, Hiller M, Just H, et al. Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int. 2011; 31: 1653-1656.
-
(2011)
Rheumatol Int
, vol.31
, pp. 1653-1656
-
-
Thonhofer, R.1
Hiller, M.2
Just, H.3
-
108
-
-
78751701824
-
Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis-efficacy of interleu-kin-6 blockade and review of the literature
-
Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still's disease with aseptic meningitis-efficacy of interleu-kin-6 blockade and review of the literature. Semin Arthritis Rheum. 2011; 40: 365-368.
-
(2011)
Semin Arthritis Rheum
, vol.40
, pp. 365-368
-
-
Sabnis, G.R.1
Gokhale, Y.A.2
Kulkarni, U.P.3
-
109
-
-
78751684939
-
Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 blockade
-
Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still's disease refractory to TNF and IL-1 blockade by IL-6 blockade. Ann Rheum Dis. 2011; 70: 390-392.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 390-392
-
-
Rech, J.1
Ronneberger, M.2
Englbrecht, M.3
-
110
-
-
79951948588
-
Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome
-
Kobayashi M, Takahashi Y, Yamashita H, et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011; 21: 92-96.
-
(2011)
Mod Rheumatol
, vol.21
, pp. 92-96
-
-
Kobayashi, M.1
Takahashi, Y.2
Yamashita, H.3
-
112
-
-
79959790777
-
Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease
-
Sekkach Y, Elqatni M, Khattabi AE, et al. Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease. Presse Med. 2011; 40: e333-e337.
-
(2011)
Presse Med
, vol.40
-
-
Sekkach, Y.1
Elqatni, M.2
Khattabi, A.E.3
-
113
-
-
84871077056
-
Therapeutic response of patients with adult Still's disease to biologic agents: Multicenter results in Japan
-
[Epub ahead of print]
-
Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2011; [Epub ahead of print].
-
(2011)
Mod Rheumatol
-
-
Suematsu, R.1
Ohta, A.2
Matsuura, E.3
-
114
-
-
33749331603
-
Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis
-
Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006; 54: 2997-3000.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2997-3000
-
-
Okuda, Y.1
Takasugi, K.2
-
115
-
-
67549125131
-
Rapid improvement of AA amy-loidosis with humanised anti-interleukin 6 receptor antibody treatment
-
Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amy-loidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009; 68: 1235-1236.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 1235-1236
-
-
Nishida, S.1
Hagihara, K.2
Shima, Y.3
-
116
-
-
70350435731
-
Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis
-
Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009; 28: 1113-1116.
-
(2009)
Clin Rheumatol
, vol.28
, pp. 1113-1116
-
-
Sato, H.1
Sakai, T.2
Sugaya, T.3
-
117
-
-
79952110725
-
Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis
-
Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010; 29: 1195-1197.
-
(2010)
Clin Rheumatol
, vol.29
, pp. 1195-1197
-
-
Inoue, D.1
Arima, H.2
Kawanami, C.3
-
118
-
-
79958084061
-
Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephritic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis
-
De La Torre M, Arboleya L, Pozo S, et al. Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephritic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. NDT Plus. 2011; 4: 178-180.
-
(2011)
NDT Plus
, vol.4
, pp. 178-180
-
-
De La Torre, M.1
Arboleya, L.2
Pozo, S.3
-
119
-
-
81255201300
-
Successful use of tocilizumab in a patient with nephritic syndrome due to a rapidly progressing AA amyloidosis to latent tuberculosis
-
Magro-Checa C, Navas-Parejo Casado A, Borrego-Garcia E, et al. Successful use of tocilizumab in a patient with nephritic syndrome due to a rapidly progressing AA amyloidosis to latent tuberculosis. Amyloid. 2011; 18: 235-239.
-
(2011)
Amyloid
, vol.18
, pp. 235-239
-
-
Magro-Checa, C.1
Navas-Parejo Casado, A.2
Borrego-Garcia, E.3
-
120
-
-
84857220265
-
Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis
-
Hattori Y, Ubara Y, Sumida K, et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid. 2012; 19: 37-40.
-
(2012)
Amyloid
, vol.19
, pp. 37-40
-
-
Hattori, Y.1
Ubara, Y.2
Sumida, K.3
-
121
-
-
77951783966
-
Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica
-
Hagihara K, Kawase I, Tanaka T, et al. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol. 2010; 37: 1075-1076.
-
(2010)
J Rheumatol
, vol.37
, pp. 1075-1076
-
-
Hagihara, K.1
Kawase, I.2
Tanaka, T.3
-
122
-
-
77951729315
-
Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab
-
Tanaka T, Hagihara K, Shima Y, et al. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Rheumatology (Oxford). 2010; 49: 824-826.
-
(2010)
Rheumatology (Oxford)
, vol.49
, pp. 824-826
-
-
Tanaka, T.1
Hagihara, K.2
Shima, Y.3
-
123
-
-
84861483650
-
A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab
-
Hirano T, Ohguro N, Hohki S, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012; 22: 298-302.
-
(2012)
Mod Rheumatol
, vol.22
, pp. 298-302
-
-
Hirano, T.1
Ohguro, N.2
Hohki, S.3
-
124
-
-
84857783564
-
Tocilizumab treatment for neu-ro-Behcet's disease, the first report
-
Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neu-ro-Behcet's disease, the first report. Clin Neurol Neurosurgery. 2011; 114: 297-298.
-
(2011)
Clin Neurol Neurosurgery
, vol.114
, pp. 297-298
-
-
Shapiro, L.S.1
Farrell, J.2
Haghighi, A.B.3
-
125
-
-
80053632353
-
Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis
-
Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocular Immunol In-flamm. 2011; 19: 382-383.
-
(2011)
Ocular Immunol In-flamm
, vol.19
, pp. 382-383
-
-
Muselier, A.1
Bielefeld, P.2
Bidot, S.3
-
126
-
-
78049508308
-
Effectiveness and safety of tocili-zumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease
-
Gergis U, Arnason J, Yantiss R, et al. Effectiveness and safety of tocili-zumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Onocol. 2010; 28: e602-e604.
-
(2010)
J Clin Onocol
, vol.28
-
-
Gergis, U.1
Arnason, J.2
Yantiss, R.3
-
127
-
-
81255163590
-
Tocilizumab for the treatment of steroid refractory graft versus host disease
-
Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft versus host disease. Biol Blood Marrow Transplant. 2011; 17: 1862-1868.
-
(2011)
Biol Blood Marrow Transplant
, vol.17
, pp. 1862-1868
-
-
Drobyski, W.R.1
Pasquini, M.2
Kovatovic, K.3
-
128
-
-
79953689919
-
Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: Assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab
-
Vaitla PM, Radford PM, Tighe PJ, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: Assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum. 2011; 63: 1151-1155.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 1151-1155
-
-
Vaitla, P.M.1
Radford, P.M.2
Tighe, P.J.3
-
129
-
-
73449141147
-
Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocili-zumab
-
Tanaka T, Kuwahara Y, Shima Y, et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocili-zumab. Arthritis Rheum. 2009; 61: 1762-1764.
-
(2009)
Arthritis Rheum
, vol.61
, pp. 1762-1764
-
-
Tanaka, T.1
Kuwahara, Y.2
Shima, Y.3
-
130
-
-
78049418460
-
Mixed response to tocilizumab for ankylosing spondylitis
-
Henes JC, Horger M, Guenaydin I, et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis. 2010; 69: 2217-2218.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 2217-2218
-
-
Henes, J.C.1
Horger, M.2
Guenaydin, I.3
-
131
-
-
78649904087
-
Short-term effect of IL-6 inhibition in spondylarthritis
-
Wendling D, Bossert M, Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine. 2010; 77: 624-625.
-
(2010)
Joint Bone Spine
, vol.77
, pp. 624-625
-
-
Wendling, D.1
Bossert, M.2
Prati, C.3
-
132
-
-
78649907237
-
Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists
-
Brulhart L, Nissen MJ, Chevallier P, et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine. 2010; 77: 625-626.
-
(2010)
Joint Bone Spine
, vol.77
, pp. 625-626
-
-
Brulhart, L.1
Nissen, M.J.2
Chevallier, P.3
-
133
-
-
83255164666
-
Tocilizumab, a humanized an-ti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis
-
Shima Y, Tomita T, Ishii T, et al. Tocilizumab, a humanized an-ti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol. 2011; 21: 436-439.
-
(2011)
Mod Rheumatol
, vol.21
, pp. 436-439
-
-
Shima, Y.1
Tomita, T.2
Ishii, T.3
-
134
-
-
79959965088
-
Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab
-
Cohen JD, Ferreira R, Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol. 2011; 38: 1527.
-
(2011)
J Rheumatol
, vol.38
, pp. 1527
-
-
Cohen, J.D.1
Ferreira, R.2
Jorgensen, C.3
-
135
-
-
84860767082
-
Interleukin 6 blockade in spon-dyloarthritis
-
Koumakis E, Feydy A, Kahan A, et al. Interleukin 6 blockade in spon-dyloarthritis. J Rheumatol. 2012; 39: 1097-1098.
-
(2012)
J Rheumatol
, vol.39
, pp. 1097-1098
-
-
Koumakis, E.1
Feydy, A.2
Kahan, A.3
-
136
-
-
84855674874
-
Tocilizumab in axial spondylarthropathies: About 18 cases
-
Dudler J, Aubry-Rozier B. Tocilizumab in axial spondylarthropathies: about 18 cases. Ann Rheum Dis. 2010; 70: 128.
-
(2010)
Ann Rheum Dis
, vol.70
, pp. 128
-
-
Dudler, J.1
Aubry-Rozier, B.2
-
137
-
-
84855672444
-
Tocilizumab for treatment of refractory spondyarthritis: Report of 5 patients
-
Del Castillo Pinol N, Gossec L, Sparsa L, et al. Tocilizumab for treatment of refractory spondyarthritis: report of 5 patients. Ann Rheum Dis. 2011; 70: 343.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 343
-
-
Del Castillo Pinol, N.1
Gossec, L.2
Sparsa, L.3
-
138
-
-
84855716888
-
Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab
-
Ogata A, Umegaki N, Katayama I, et al. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine. 2012; 79: 85-87.
-
(2012)
Joint Bone Spine
, vol.79
, pp. 85-87
-
-
Ogata, A.1
Umegaki, N.2
Katayama, I.3
-
139
-
-
70350571214
-
Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease
-
Taniguchi K, Shimazaki C, Fujimoto Y, et al. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. Int J Hematol. 2009; 90: 99-102.
-
(2009)
Int J Hematol
, vol.90
, pp. 99-102
-
-
Taniguchi, K.1
Shimazaki, C.2
Fujimoto, Y.3
-
140
-
-
77956051502
-
The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease
-
Arita Y, Sakata Y, Sudo T, et al. The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. Heart Vessels. 2010; 25: 444-447.
-
(2010)
Heart Vessels
, vol.25
, pp. 444-447
-
-
Arita, Y.1
Sakata, Y.2
Sudo, T.3
-
141
-
-
79955116824
-
Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension
-
Article ID 720305
-
Furuya Y, Satoh T, Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol. 2010; Article ID 720305
-
(2010)
Int J Rheumatol
-
-
Furuya, Y.1
Satoh, T.2
Kuwana, M.3
-
142
-
-
80055076585
-
Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial su-perinfection
-
Navarini AA, French LE, Hofbauer GFL. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial su-perinfection. J Allergy Clin Immunol. 2011; 128: 1128-1130.
-
(2011)
J Allergy Clin Immunol
, vol.128
, pp. 1128-1130
-
-
Navarini, A.A.1
French, L.E.2
Hofbauer, G.F.L.3
-
143
-
-
84868142444
-
Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica
-
[Epub ahead of print]
-
Ohtori S, Miyagi M, Eguchi Y, et al. Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica. Eur Spine J. 2012; [Epub ahead of print].
-
(2012)
Eur Spine J
-
-
Ohtori, S.1
Miyagi, M.2
Eguchi, Y.3
-
144
-
-
79955807238
-
Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocili-zumab
-
Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocili-zumab. Ann Rheum Dis. 2011; 70: 1164-1165.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1164-1165
-
-
Ogata, A.1
Morishima, A.2
Hirano, T.3
-
145
-
-
78650781728
-
Effects of inhibition of interleu-kin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases
-
Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleu-kin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010; 5: e14328.
-
(2010)
PLoS One
, vol.5
-
-
Schultz, O.1
Oberhauser, F.2
Saech, J.3
-
146
-
-
84872272661
-
Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab
-
[Epub ahead of print]
-
Hirao M, Yamasaki N, Oze H, et al. Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. Rheumatol Int. 2011; [Epub ahead of print].
-
(2011)
Rheumatol Int
-
-
Hirao, M.1
Yamasaki, N.2
Oze, H.3
-
147
-
-
84859218984
-
The interleukin-6 pathway and atherosclerosis
-
Matthijs Boekholdt S, Stores ESG. The interleukin-6 pathway and atherosclerosis. Lancet. 2012, 379: 1176-1178.
-
(2012)
Lancet
, vol.379
, pp. 1176-1178
-
-
Matthijs Boekholdt, S.1
Stores, E.S.G.2
-
148
-
-
84859210770
-
Interleukin-6 receptor pathways in coronary heart disease: A collaborative meta-analysis of 82 studies
-
IL-6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, et al
-
IL-6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012; 379: 1205-1213.
-
(2012)
Lancet
, vol.379
, pp. 1205-1213
-
-
-
149
-
-
84859215358
-
The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis
-
The Interleukin-6 Receptor Mendelian Randomization Analysis (IL-6R MR) Consortium, Hingorani AD, Casas JP
-
The Interleukin-6 Receptor Mendelian Randomization Analysis (IL-6R MR) Consortium, Hingorani AD, Casas JP. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012; 379: 1214-1224.
-
(2012)
Lancet
, vol.379
, pp. 1214-1224
-
-
-
150
-
-
84857411475
-
Hitting a complex target: An update on inter-leukin-6 trans-signaling
-
Waetzig GH, Rose-John S. Hitting a complex target: an update on inter-leukin-6 trans-signaling. Expert Opin Ther Targets. 2012; 16: 225-236.
-
(2012)
Expert Opin Ther Targets
, vol.16
, pp. 225-236
-
-
Waetzig, G.H.1
Rose-John, S.2
-
151
-
-
84871084229
-
Tocilizumab for the treatment of AA amyloidosis
-
Guvenc IA, ed., Croatia: INTECH Open Access Publisher
-
Tanaka T, Hagihara K, Hishitani Y, et al. Tocilizumab for the treatment of AA amyloidosis. In: Guvenc IA, ed. Amyloidosis - An insight to disease of systems and novel therapies. Croatia: INTECH Open Access Publisher; 2011: 155-170.
-
(2011)
Amyloidosis - An Insight to Disease of Systems and Novel Therapies
, pp. 155-170
-
-
Tanaka, T.1
Hagihara, K.2
Hishitani, Y.3
-
152
-
-
78149324897
-
Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Cas-tleman disease
-
Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Cas-tleman disease. Blood. 2010; 116: 3627-3634.
-
(2010)
Blood
, vol.116
, pp. 3627-3634
-
-
Song, S.N.1
Tomosugi, N.2
Kawabata, H.3
-
153
-
-
84871059465
-
Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients
-
[Epub ahead of print]
-
Samson M, Audia S, Janikashvili N, et al. Inhibition of IL-6 function corrects Th17/Treg imbalance in rheumatoid arthritis patients. Arthritis Rheum. 2012; [Epub ahead of print].
-
(2012)
Arthritis Rheum
-
-
Samson, M.1
Audia, S.2
Janikashvili, N.3
-
154
-
-
79955569760
-
In vivo effects of the an-ti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment
-
Roll P, Muhammad K, Schumann M, et al. In vivo effects of the an-ti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011; 63: 1255-1264.
-
(2011)
Arthritis Rheum
, vol.63
, pp. 1255-1264
-
-
Roll, P.1
Muhammad, K.2
Schumann, M.3
-
155
-
-
79959807954
-
Impact of IL-6 receptor inhibition on human memory B cells in vivo: Impaired somatic hypermutation in preswitch memory B cells and mutational targeting in memory B cells
-
Muhammad K, Roll P, Seibold T, et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and mutational targeting in memory B cells. Ann Rheum Dis. 2011; 70: 1507-1510.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1507-1510
-
-
Muhammad, K.1
Roll, P.2
Seibold, T.3
-
156
-
-
79952762854
-
Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neu-romyelitis optica
-
Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neu-romyelitis optica. Proc Natl Acad Sci USA. 2011; 108: 3701-3706.
-
(2011)
Proc Natl Acad Sci USA
, vol.108
, pp. 3701-3706
-
-
Chihara, N.1
Aranami, T.2
Sato, W.3
-
157
-
-
0026611673
-
IL-6 and NF-IL6 in acute-phase response and viral infection
-
Akira S, Kishimoto T. IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev. 1992; 127: 25-50.
-
(1992)
Immunol Rev
, vol.127
, pp. 25-50
-
-
Akira, S.1
Kishimoto, T.2
-
158
-
-
0027453552
-
Transcriptional factor NF-IL-6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8
-
Matsusaka T, Fujikawa K, Nishio Y, et al. Transcriptional factor NF-IL-6 and NF-κB synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA. 1993; 90: 10193-10197.
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 10193-10197
-
-
Matsusaka, T.1
Fujikawa, K.2
Nishio, Y.3
-
159
-
-
38349114778
-
P38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements
-
Zhao W, Liu M, Kirkwood KL. P38alpha stabilizes interleukin-6 mRNA via multiple AU-rich elements. J Biol Chem 2008; 283: 1778-1785.
-
(2008)
J Biol Chem
, vol.283
, pp. 1778-1785
-
-
Zhao, W.1
Liu, M.2
Kirkwood, K.L.3
-
160
-
-
81255154489
-
The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1
-
Iwasaki H, Takeuchi O, Teraguchi S, et al. The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1. Nat Immunol. 2011; 12: 1167-1175.
-
(2011)
Nat Immunol
, vol.12
, pp. 1167-1175
-
-
Iwasaki, H.1
Takeuchi, O.2
Teraguchi, S.3
-
161
-
-
79952386909
-
Kaposi's sarcoma-associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression
-
Kang JG, Pripuzova N, Majerciak V, et al. Kaposi's sarcoma-associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression. J Virol. 2011; 85: 2620-2630.
-
(2011)
J Virol
, vol.85
, pp. 2620-2630
-
-
Kang, J.G.1
Pripuzova, N.2
Majerciak, V.3
-
162
-
-
74949116731
-
Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes
-
Qin Z, Keamey P, Plaisance K, et al. Pivotal advance: Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. J Leu-koc Biol. 2010; 87: 25-34.
-
(2010)
J Leu-koc Biol
, vol.87
, pp. 25-34
-
-
Qin, Z.1
Keamey, P.2
Plaisance, K.3
-
163
-
-
0023900857
-
HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor
-
Leung K, Nabel GJ. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature. 1988; 333: 776-778.
-
(1988)
Nature
, vol.333
, pp. 776-778
-
-
Leung, K.1
Nabel, G.J.2
-
164
-
-
0023712373
-
HTLV-1 tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene
-
Ballard DW, Bohnlein E, Lowenthal JW, et al. HTLV-1 tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science. 1988; 241: 1652-1655.
-
(1988)
Science
, vol.241
, pp. 1652-1655
-
-
Ballard, D.W.1
Bohnlein, E.2
Lowenthal, J.W.3
-
165
-
-
0027955428
-
The expression of the interleu-kin 6 gene is induced by the human immunodeficiency virus 1 TAT protein
-
Scala G, Ruocco MR, Ambrosino C, et al. The expression of the interleu-kin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med. 1994; 179: 961-971.
-
(1994)
J Exp Med
, vol.179
, pp. 961-971
-
-
Scala, G.1
Ruocco, M.R.2
Ambrosino, C.3
-
166
-
-
0030914237
-
HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors
-
Ambrosino C, Ruocco MR, Chen X, et al. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors. J Biol Chem. 1997; 272: 14883-14892.
-
(1997)
J Biol Chem
, vol.272
, pp. 14883-14892
-
-
Ambrosino, C.1
Ruocco, M.R.2
Chen, X.3
-
167
-
-
0025768552
-
Hepatitis B virus X protein transac-tivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT /enhancer-binding protein-like cis-elements
-
Mahe Y, Mukaida N, Kuno K, et al. Hepatitis B virus X protein transac-tivates human interleukin-8 gene through acting on nuclear factor kB and CCAAT /enhancer-binding protein-like cis-elements. J Biol Chem. 1991; 266: 13759-13763.
-
(1991)
J Biol Chem
, vol.266
, pp. 13759-13763
-
-
Mahe, Y.1
Mukaida, N.2
Kuno, K.3
-
168
-
-
0032959637
-
Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain
-
Ohno H, Kaneko S, Lin Y, et al. Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. J Med Virol. 1999; 58: 11-18.
-
(1999)
J Med Virol
, vol.58
, pp. 11-18
-
-
Ohno, H.1
Kaneko, S.2
Lin, Y.3
|